Tazeen Ahmad
Stock Analyst at B of A Securities
(3.45)
# 944
Out of 5,051 analysts
212
Total ratings
46.79%
Success rate
4.62%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Initiates: Buy | $53 | $27.99 | +89.35% | 1 | Oct 9, 2025 | |
| PHVS Pharvaris | Upgrades: Neutral | $16 → $27 | $21.72 | +24.31% | 4 | Oct 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $453 → $520 | $434.56 | +19.66% | 5 | Sep 17, 2025 | |
| INCY Incyte | Maintains: Buy | $90 → $104 | $105.70 | -1.61% | 6 | Sep 4, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $227 → $230 | $197.75 | +16.31% | 11 | Sep 2, 2025 | |
| ARGX argenx SE | Maintains: Buy | $880 → $887 | $832.35 | +6.57% | 4 | Sep 2, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Underperform | $17 → $16 | $18.67 | -14.30% | 26 | Aug 21, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $82 → $76 | $71.77 | +5.89% | 19 | Aug 20, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $23 → $27 | $22.33 | +20.91% | 16 | Aug 7, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $126 → $134 | $103.43 | +29.56% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $24 | $19.95 | +20.30% | 8 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.03 | +98.51% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $95 | $99.47 | -4.49% | 9 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.17 | +109.21% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $10.27 | -61.05% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $1 → $0.8 | $0.98 | -18.71% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $14.89 | +81.33% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $9.57 | +192.58% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $95.18 | -26.46% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $10.51 | +280.59% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $153.75 | +16.42% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $10.99 | +100.18% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $4.54 | -33.92% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $9.19 | +63.22% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $7.87 | -74.59% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $31.87 | +138.47% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.01 | +232.23% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.09 | +450.46% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $10.81 | +38.76% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $4.00 | -50.00% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $1.39 | +331.65% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $12.42 | +20.77% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $164.64 | -63.56% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $3.91 | +309.21% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $189.97 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $14.10 | +2,027.66% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.43 | +270.37% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $21.85 | +119.68% | 6 | Oct 10, 2018 |
Scholar Rock Holding
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $27.99
Upside: +89.35%
Pharvaris
Oct 9, 2025
Upgrades: Neutral
Price Target: $16 → $27
Current: $21.72
Upside: +24.31%
Alnylam Pharmaceuticals
Sep 17, 2025
Maintains: Buy
Price Target: $453 → $520
Current: $434.56
Upside: +19.66%
Incyte
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $105.70
Upside: -1.61%
Ascendis Pharma
Sep 2, 2025
Maintains: Buy
Price Target: $227 → $230
Current: $197.75
Upside: +16.31%
argenx SE
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $832.35
Upside: +6.57%
Sarepta Therapeutics
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $18.67
Upside: -14.30%
PTC Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $82 → $76
Current: $71.77
Upside: +5.89%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $27
Current: $22.33
Upside: +20.91%
BioNTech SE
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $103.43
Upside: +29.56%
Jul 16, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $19.95
Upside: +20.30%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $4.03
Upside: +98.51%
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $99.47
Upside: -4.49%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $7.17
Upside: +109.21%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $10.27
Upside: -61.05%
May 19, 2025
Maintains: Underperform
Price Target: $1 → $0.8
Current: $0.98
Upside: -18.71%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $14.89
Upside: +81.33%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $9.57
Upside: +192.58%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $95.18
Upside: -26.46%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $10.51
Upside: +280.59%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $153.75
Upside: +16.42%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $10.99
Upside: +100.18%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $4.54
Upside: -33.92%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $9.19
Upside: +63.22%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $7.87
Upside: -74.59%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $31.87
Upside: +138.47%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $3.01
Upside: +232.23%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.09
Upside: +450.46%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $10.81
Upside: +38.76%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $4.00
Upside: -50.00%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $1.39
Upside: +331.65%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $12.42
Upside: +20.77%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $164.64
Upside: -63.56%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $3.91
Upside: +309.21%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $189.97
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $14.10
Upside: +2,027.66%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.43
Upside: +270.37%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $21.85
Upside: +119.68%